Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma
NCT05001880
Recruiting
This phase II trial compares the usual treatment alone (carboplatin, pemetrexed, and bevacizumab) to using immunotherapy (atezolizumab) plus the usual treatment in treating patients with peritoneal mesothelioma. The usual treatment consists of surgery or chemotherapy. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slow... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Mayo Clinic Hospital in Arizona, Phoenix, Arizona +38 locations
Conditions: Peritoneal Malignant Mesothelioma
Register for Updates
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
NCT05024773
Recruiting
This is a phase III, single-arm, multicenter, international study to assess the efficacy and safety of ONCOFID-P-B following intravesical instillation in adult patients with histologically and cytologically confirmed CIS, with or without concomitant Ta-T1, who are unresponsive to BCG therapy and unwilling or unfit to undergo radical cystectomy. After providing written informed consent (in presence of an Independent Witness, if applicable), patients will receive an induction therapy consisting o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Banner Health- MD Anderson Cancer Center, Gilbert, Arizona +45 locations
Conditions: Bladder Carcinoma in Situ (CIS)
Register for Updates
Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome
NCT05035030
Recruiting
The purpose of this study is to assess the long-term safety and effectiveness of odevixibat in participants with Alagille syndrome (ALGS). The participants of this study will have ALGS a rare genetic disorder that can affect multiple organ systems of the body including the liver, heart, skeleton, eyes and kidneys. Common symptoms, which often develop during the first three months of life, include blockage of the flow of bile from the liver (cholestasis), yellowing of the skin and mucous membran... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/29/2025
Locations: Rady Children's Hospital, San Diego, California +29 locations
Conditions: Alagille Syndrome
Register for Updates
Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy
NCT05069038
Recruiting
Patients with estrogen receptor positive (ER+) and/or progesterone receptor positive (PR+) breast cancer do not achieve good responses with pre-operative chemotherapy. The sensitivity of breast cancer to chemotherapy is often determined by the underlying gene expression pattern and the molecular subtype of the tumor. In addition, not all patients tolerate chemotherapy well. Pre-operative endocrine therapy has emerged as an effective strategy to improve outcomes in patients with early-stage hormo... Read More
Gender:
FEMALE
Ages:
19 years and above
Trial Updated:
07/29/2025
Locations: Unversity of Nebraska Medical Center, Omaha, Nebraska
Conditions: Breast Cancer
Register for Updates
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
NCT05103683
Recruiting
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Providence Medical Foundation, Fullerton, California +13 locations
Conditions: Advanced Solid Tumor, Ovarian Cancer, Endometrial Cancer, NSCLC
Register for Updates
A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
NCT05117476
Recruiting
CLN-619-001 is a Phase 1, open-label, multi-center study of CLN-619 alone and in combination with pembrolizumab in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +22 locations
Conditions: Advanced Solid Tumor, NSCLC
Register for Updates
Family Functioning in Obesity Treatment for Mexican Americans
NCT05120804
Recruiting
Mexican American families share similar elevated risks for obesity and obesity-related conditions, such as type 2 diabetes. Because negative family interactions and relationships (e.g., poor communication, high conflict, low emotional closeness) are associated with obesity treatment outcomes, this study tests a behavioral weight management intervention that provides relationship skills counseling to mothers and adult daughters. The goal is to improve family interaction patterns to buffer challen... Read More
Gender:
FEMALE
Ages:
Between 18 years and 65 years
Trial Updated:
07/29/2025
Locations: University of California San Diego, La Jolla, California +1 locations
Conditions: Obesity
Register for Updates
Evolut™ EXPAND TAVR II Pivotal Trial
NCT05149755
Recruiting
Obtain safety and effectiveness data to support indication expansion for the Medtronic TAVR System to include patients with moderate, AS.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/29/2025
Locations: University of Alabama at Birmingham (UAB) Hospital, Birmingham, Alabama +98 locations
Conditions: Moderate Aortic Valve Stenosis
Register for Updates
The Less is More Study
NCT05153811
Recruiting
In this project, the investigators will implement innovations to extend use of Contingency Management (CM) to facilitate alcohol use reduction among people living with HIV (PLWH). The investigators' approach to extending CM will use mobile health (mHealth) tools including a smartphone breathalyzer device with accompanying app and a wrist worn alcohol biosensor. Participants will be engaged in mobile facilitated CM for 30-60 days with follow-up out to 6 months.
Gender:
ALL
Ages:
Between 35 years and 70 years
Trial Updated:
07/29/2025
Locations: University of Miami, Coral Gables, Florida +1 locations
Conditions: Alcohol Use
Register for Updates
Serial Ultrasound of Solid Tumor Lesions to Detect Early Response to Cancer Immunotherapy
NCT05206942
Recruiting
Primary objective is to assess whether changes in quantitative tumor perfusion parameters after 3 weeks of treatment, as measured by CEUS, can predict initial objective response to therapy, defined by current standard-of-care Secondary objectives are to evaluate if there is an optimal ultrasound imaging modality (CEUS or conventional power Doppler or LEAD ultrasound) or optimal time point to predict initial objective response and to assess the correlation of tumor perfusion parameters with chan... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Stanford, Palo Alto, California
Conditions: Solid Tumor
Register for Updates
Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma
NCT05284643
Recruiting
The purpose of this research is to find hidden cancer with an experimental magnetic resonance imaging (MRI) scan called spectroscopic magnetic resonance imaging (sMRI). That spectroscopic MRI scan will be used to increase the area of the brain receiving radiation and then the dose of radiation in attempt to kill more of the cancer. Proton radiotherapy and bevacizumab (Avastin) are used to minimize the possible side effects of this approach.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: University of Miami, Miami, Florida
Conditions: Recurrent Glioblastoma
Register for Updates
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
NCT05303064
Recruiting
To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
07/29/2025
Locations: Alkermes Investigator Site, Dothan, Alabama +46 locations
Conditions: Schizophrenia, Bipolar I Disorder
Register for Updates